Breast cancer and endocrine-sensitive disease
Research activity includes ER-positive/HER2-negative early breast cancer, operable invasive disease in premenopausal patients, and isolated locoregional recurrence of HR-positive, HER2-negative breast cancer. The portfolio also covers endocrine therapy combinations and post-recurrence treatment strategies.
- Hormone receptor-positive breast cancer
- HER2-negative early breast cancer
- Isolated locoregional recurrence
- Adjuvant endocrine therapy
Interest extends to treatment approaches that address residual risk after surgery and recurrence patterns in breast cancer.
Non-small cell lung cancer in resectable and locally advanced settings
Several studies focus on NSCLC across early, resectable, and locally advanced stages, including stage II-IIIA disease, stage IIB-IIIB (N2) resectable tumours, and unresectable stage III disease after chemoradiotherapy. The sponsor also supports work in synchronous oligo-metastatic NSCLC.
- Resected NSCLC
- Locally advanced NSCLC
- Oligo-metastatic disease
- Adjuvant and consolidation treatment
These areas reflect sustained interest in postoperative management, locoregional control, and disease-free survival in surgically treated lung cancer.
Biomarker-defined advanced lung cancer
The sponsor funds trials in molecularly selected NSCLC, including EGFR-mutant disease after prior EGFR-TKI therapy, KRASG12C-mutant NSCLC, and ALK-rearranged locally advanced disease. Trials also address patients with reduced functional status and older adults.
- EGFR-mutant NSCLC
- KRASG12C-mutant NSCLC
- ALK-rearranged NSCLC
- Elderly and poor-performance-status patients
Research interest is concentrated on targeted treatment options for genetically defined lung cancer populations with limited standard options.
Small cell lung cancer and immune-responsive disease
Clinical research includes extensive-disease small cell lung cancer and pretreated ES-SCLC, with attention to patients with SLFN11-positive tumours and those with ECOG PS 2. The sponsor also supports studies in disease that has progressed after prior chemo-immunotherapy.
- Extensive-stage small cell lung cancer
- SLFN11-positive disease
- Post–chemo-immunotherapy progression
- Patients with limited performance status
These trials reflect a focus on aggressive small cell lung cancer and biomarker-linked treatment selection.
